CML
56 programs · 53 companies
Programs
56
Companies
53
Trials
56
MOAs
29
BCL-2iEZH2iKRASG12DiCDK2iAuroraAiSTINGagHER2CAR-T CD19CGRPantGLP-1/GIP
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Geliderotide | NDA/BLA | IL-17A | ||
| Ribotuximab | Phase 2 | GPRC5D | ||
| Pexarelsin | Phase 1 | DLL3 | ||
| Tirasotorasib | NDA/BLA | IL-17A | ||
| TAK-5300 | Phase 1 | SMN2 | ||
| GIL-4361 | Preclinical | PCSK9 | ||
| Adagrarapivir | Phase 1/2 | IL-17A | ||
| Zanumavacamten | Phase 2 | FLT3 | ||
| Polaglumide | Phase 3 | TYK2 | ||
| Voxabrutinib | Phase 1/2 | EZH2 | ||
| PST-2276 | Approved | Aβ | ||
| TXG-6755 | Approved | CD123 | ||
| Polalucimab | Phase 3 | MALT1 | ||
| SUN-5027 | Preclinical | DLL3 | ||
| Zanulemzoparlimab | NDA/BLA | KRASG12D | ||
| CHI-IIT-162 | Preclinical | DLL3 | ||
| PEK-IIT-150 | Phase 1 | MALT1 | ||
| NCI-IIT-396 | Approved | CGRP | ||
| MOR-923 | Preclinical | CD123 | ||
| Rimatenlimab | Phase 1/2 | MDM2 | ||
| RIN-657 | Phase 1 | CDK2 | ||
| DEE-8943 | Phase 2/3 | WRN | ||
| INH-5545 | Phase 3 | CD19 | ||
| Polarapivir | NDA/BLA | FcRn | ||
| GAL-3172 | Preclinical | CFTR | ||
| Gozederotide | Preclinical | EZH2 | ||
| Lirainavolisib | Approved | ALK | ||
| SIE-6456 | Phase 2 | MALT1 | ||
| Elrazumab | NDA/BLA | CD3 | ||
| FLA-5216 | Approved | CD47 | ||
| Mirirasimod | Approved | FLT3 | ||
| 109-3699 | Phase 2 | GLP-1R | ||
| GC-6461 | Preclinical | CDK4/6 | ||
| AMB-7870 | Phase 3 | IL-13 | ||
| Rimasacituzumab | Phase 2 | FcRn | ||
| Niraglumide | Preclinical | AHR | ||
| SEN-3594 | Phase 2/3 | LAG-3 | ||
| Mirifotisoran | Approved | BET | ||
| Daratuximab | Approved | CFTR | ||
| Zorivorutinib | NDA/BLA | CGRP | ||
| Zoriratamab | Approved | SOS1 | ||
| BDT-405 | Phase 1/2 | CD123 | ||
| Fixalucimab | NDA/BLA | HER2 | ||
| REC-373 | Phase 1 | SGLT2 | ||
| PLU-3424 | Phase 2 | SHP2 | ||
| FER-2526 | NDA/BLA | CD47 | ||
| Poladerotide | Phase 3 | DLL3 | ||
| Niratinib | Preclinical | CD20 | ||
| THA-9190 | Preclinical | WEE1 | ||
| CHA-IIT-311 | Phase 2 | WRN | ||
| NAT-IIT-794 | Approved | Cl18.2 | ||
| CAM-IIT-461 | Phase 1 | Cl18.2 | ||
| MSN-5549 | NDA/BLA | FcRn | ||
| 002-2150 | Phase 2 | GIP-R | ||
| Tixalucimab | Phase 1/2 | MALT1 | ||
| Motanaritide | Approved | B7-H3 |
Trials (56)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT07346189 | Geliderotide | NDA/BLA | Terminated |
| NCT08259675 | Ribotuximab | Phase 2 | Completed |
| NCT04821093 | Ribotuximab | Phase 2 | Recruiting |
| NCT07310733 | Tirasotorasib | NDA/BLA | Terminated |
| NCT05964318 | TAK-5300 | Phase 1 | Recruiting |
| NCT05878698 | GIL-4361 | Preclinical | Recruiting |
| NCT07080299 | Adagrarapivir | Phase 1/2 | Terminated |
| NCT07777971 | Adagrarapivir | Phase 1/2 | Active |
| NCT04670920 | Polaglumide | Phase 3 | Completed |
| NCT04244914 | Voxabrutinib | Phase 1/2 | Completed |
| NCT04384552 | PST-2276 | Approved | Completed |
| NCT06419051 | PST-2276 | Approved | Completed |
| NCT06408929 | TXG-6755 | Approved | Terminated |
| NCT06666673 | Polalucimab | Phase 3 | Active |
| NCT08440621 | Polalucimab | Phase 3 | Recruiting |
| NCT03254322 | Polalucimab | Phase 3 | Not yet recr... |
| NCT06986885 | SUN-5027 | Preclinical | Recruiting |
| NCT05982419 | CHI-IIT-162 | Preclinical | Recruiting |
| NCT07999844 | PEK-IIT-150 | Phase 1 | Recruiting |
| NCT04998820 | NCI-IIT-396 | Approved | Active |